Search Results - "Roderburg C"

Erkennen und Behandeln von Nebenwirkungen der Immuntherapie.

Alternate Title: Recognition and management of immunotherapy-related toxicity.

Authors: Leyh, C. Roderburg, C. Lüdde, T.

Source: Best Practice Onkologie. May2026, Vol. 21 Issue 5, p184-190. 7p.

This result is not displayed to guests.
Login for full access.

The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells.

Authors: Faber A Roderburg C Wein F et al.

Source: Journal of Biomedicine & Biotechnology. 2007 Regular Issue, p1-10. 10p.

URL: 28142554

321P Results of an open-label, single-arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC).

Authors: Roderburg, C. Gonzalez Carmona, M.A. Berres, M-L. et al.

Source: Annals of Oncology. 2025 Supplement 1, Vol. 36, pS125-S125. 1p.

Most oncological pancreas resections must consider the mesopancreas.

Authors: Safi, S. A. David, S. Haeberle, L. et al.

Source: BMC Cancer. 2/4/2025, Vol. 25 Issue 1, p1-9. 9p.

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.

Authors: Sommerhäuser, G. Kurreck, A. Stintzing, S. et al.

Source: BMC Cancer. 7/27/2022, Vol. 22 Issue 1, p1-14. 14p.

Aktueller Therapiealgorithmus des intrahepatischen cholangiozellulären Karzinoms.

Alternate Title: Intrahepatic cholangiocarcinoma - current perspectives and treatment algorithm.

Authors: Lurje, G. Bednarsch, J. Roderburg, C. et al.

Source: Der Chirurg. Nov2018, Vol. 89 Issue 11, p858-864. 7p.

Minimally invasive versus open surgery for colonic diverticular disease: a nationwide analysis of German hospital data.

Authors: Kolbe, E. W. Buciunas, M. Krieg, S. et al.

Source: Techniques in Coloproctology. 1/16/2025, Vol. 29 Issue 1, p1-10. 10p.

601 miR-133a MEDIATES TGF-b-DEPENDENT DE-REPRESSION OF COLLAGEN-SYNTHESIS IN HEPATIC STELLATE CELLS DURING LIVER FIBROSIS.

Authors: Roderburg, C. Cardenas, D.V. Hellerbrand, C. et al.

Source: Journal of Hepatology. Apr2013 Supplement 1, Vol. 58, pS245-S246. 0p.

590 MICRO-RNA PROFILING IN HUMAN SERUM REVEALS ETIOLOGY-INDEPENDENT, COMPARTMENT-SPECIFIC ROLES OF MIR-571 AND MIR-652 IN LIVER CIRRHOSIS

Authors: Roderburg, C. Cardenas, D. Vargas Vucur, M. et al.

Source: Journal of Hepatology. Apr2012 Supplement, Vol. 56 Issue s2, pS234-S234. 1p.

EPH191 Iron Deficiency Anemia Is Associated with Colorectal and Stomach Cancer Diagnoses in Germany.

Authors: Kostev, K. Schlecht, J. Roderburg, C. et al.

Source: Value in Health. 2023 Supplement, Vol. 26 Issue 12, pS238-S238. 1p.

1502P CaboRISE (AIO-HEP-0320/ass.): A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with preserved liver function.

Authors: Koch, C. Waldschmidt, D.T. Goetze, T.O. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS901-S901. 1p.

107eP Safety of ivosidenib in patients with mIDH1 CCA: Updated results from the phase IIIb ProvIDHe study.

Authors: Casadei Gardini, A. Wilmink, H. Bridgewater, J.A. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS244-S244. 1p.

357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial.

Authors: Goetze, T.O. Vogel, A. Gonzalez Carmona, M.A. et al.

Source: Annals of Oncology. 2025 Supplement 1, Vol. 36, pS140-S140. 1p.

262MO Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study.

Authors: Bridgewater, J.A. Gardini, A. Casadei Wilmink, H. et al.

Source: Annals of Oncology. 2025 Supplement 1, Vol. 36, pS103-S103. 1p.

LBA25 Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316).

Authors: Kasper-Virchow, S. Hofheinz, R.D. Stintzing, S. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1218-S1218. 1p.

124: Molecular composition of cell-cell contact between hematopoietic stem cells and mesenchymal stem cells

Authors: Wagner, W. Wein, F. Roderburg, C. et al.

Source: Biology of Blood & Marrow Transplantation. Feb2007 Supplement, Vol. 13, p47-48. 2p.

191P Evaluating sorafenib as second-line treatment for advanced hepatocellular carcinoma: SORA-2, an European retrospective multicenter study.

Authors: Möhring, C. Berger, M. Sadeghlar, F. et al.

Source: Annals of Oncology. 2024 Supplement 1, Vol. 35, pS86-S86. 1p.

Randomized Clinical Trial: Perioperative Rifaximin Is Not Associated with Enhanced Functional and Volumetric Recovery after Major Liver Resection (ARROW).

Authors: Bednarsch, J. Czigany, Z. Loosen, S.H. et al.

Source: HPB (1365-182X). 2022 Supplement1, Vol. 24, pS167-S167. 1p.

P236 RIP3-DEPENDENT NECROPTOSIS CONTROLS NON-ALCOHOLIC STEATOHEPATITIS INDUCED LIVER FIBROSIS VIA JNK.

Authors: Gautheron, J. Vucur, M. Reisinger, F. et al.

Source: Journal of Hepatology. Apr2014 Supplement, Vol. 60, pS144-S144. 1p.